Jennifer Shade
Nurse Practitioner · Lewes, DENPI 1730577388
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.7% of the total across 196 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 35 manufacturers, the largest accounting for just 14.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $1,202 and has fallen 62.4% since, to $452 in 2025. Among nurse practitioner clinicians in DE with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 196 payments — averaging $18.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$508
- Lilly USA, LLC$453
- AstraZeneca$395
- Astellas Pharma US Inc$295
- AbbVie$263
- Boehringer Ingelheim$195
- plus $1K from 29 others
What the payments were for
- Food & beverage$3,35795%
- Education$1865%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 30 | $508 |
| Lilly USA, LLC | 29 | $453 |
| AstraZeneca(2 entities) | 17 | $395 |
| Astellas Pharma US Inc | 10 | $295 |
| AbbVie | 15 | $263 |
| Boehringer Ingelheim | 15 | $195 |
| Daiichi Sankyo Inc. | 9 | $156 |
| Amgen(2 entities) | 8 | $136 |
| Exact Sciences | 7 | $136 |
| Pfizer | 8 | $132 |
| Bayer | 7 | $117 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $116 |
| Lundbeck LLC | 5 | $95 |
| Xeris Pharmaceuticals, Inc. | 2 | $47 |
| Sumitomo Pharma America, Inc. | 2 | $45 |
| Otsuka America Pharmaceutical, Inc. | 2 | $42 |
| Johnson & Johnson | 1 | $37 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $33 |
| Merck | 2 | $32 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $32 |
| Kowa Pharmaceuticals America, Inc. | 2 | $28 |
| Idorsia Pharmaceuticals US Inc | 1 | $25 |
| Dexcom, Inc. | 1 | $22 |
| Neurelis, Inc. | 1 | $21 |
| VBI Vaccine (delaware) Inc. | 1 | $20 |
| GSK | 1 | $19 |
| Esperion Therapeutics, Inc. | 1 | $19 |
| Phathom Pharmaceuticals, Inc. | 1 | $19 |
| Linus Health, Inc. | 1 | $19 |
| Indivior Inc. | 1 | $18 |
| Bausch Health US, LLC | 1 | $17 |
| Amneal Pharmaceuticals LLC | 1 | $14 |
| Ultragenyx Pharmaceutical Inc. | 1 | $13 |
| Sanofi-aventis U.S. LLC | 1 | $13 |
| Biohaven Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,543 in reported general payments places this provider in the 90th percentile of 487 nurse practitioner providers in Delaware.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 51 | $98,714 |
| JardianceEmpagliflozin | 60 | $83,722 |
| MounjaroTirzepatide | 39 | $53,829 |
| EliquisApixaban | 33 | $38,898 |
| TrulicityDulaglutide | 14 | $36,562 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 18 | $18,828 |
| Rosuvastatin Calcium | 368 | $6,899 |
| Atorvastatin Calcium | 452 | $4,183 |
| Levothyroxine Sodium | 372 | $3,966 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 18 | $3,560 |
| SynthroidLevothyroxine Sodium | 64 | $3,331 |
| Bupropion XlBupropion Hcl | 62 | $3,010 |
| Gabapentin | 105 | $2,929 |
| Metoprolol Succinate | 140 | $2,329 |
| Amlodipine Besylate | 282 | $2,295 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $508 | $98,71451 claims |
| Lilly USA, LLCMounjaro, Trulicity | $453 | $90,39153 claims |
| Boehringer IngelheimJardiance | $195 | $83,72260 claims |
| PfizerEliquis | $132 | $38,89833 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $13 | $18,82818 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $14 | $3,966372 claims |
| AbbVieSynthroid | $263 | $3,33164 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 487 nurse practitioner providers in Delaware.
Other nurse practitioner in Lewes
- Shelby HoganLewes$5K
- Susan ParksLewes$3K
- Amanda CaputoLewes$3K
- Jennifer WilleyLewes$3K
- Deborah TabulovLewes$2K
- Meghan McCarterSeaford$170K
- Chandni PatelMiddletown$113K
- Craig LaingMilford$51K
- Colleen DitroWilmington$16K
- Sedelle Henderson-BamideleNewark$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.